Incidence and prognosis of ventilator-associated pneumonia in critically ill patients with covid-19: A multicenter study

Daniele Roberto Giacobbe, Denise Battaglini, Elisa Martina Enrile, Chiara Dentone, Antonio Vena, Chiara Robba, Lorenzo Ball, Michele Bartoletti, Irene Coloretti, Stefano Di Bella, Antonio Di Biagio, Iole Brunetti, Malgorzata Mikulska, Novella Carannante, Andrea De Maria, Laura Magnasco, Alberto Enrico Maraolo, Michele Mirabella, Giorgia Montrucchio, Nicolò PatronitiLucia Taramasso, Giusy Tiseo, Giacomo Fornaro, Fiorentino Fraganza, Luca Monastra, Erik Roman-Pognuz, Giacomo Paluzzano, Giuseppe Fiorentino, Antonio Corcione, Linda Bussini, Renato Pascale, Silvia Corcione, Tommaso Tonetti, Matteo Rinaldi, Marco Falcone, Emanuela Biagioni, Vito Marco Ranieri, Maddalena Giannella, Francesco Giuseppe De Rosa, Massimo Girardis, Francesco Menichetti, Pierluigi Viale, Paolo Pelosi, Matteo Bassetti

Research output: Contribution to journalArticlepeer-review

Abstract

The primary objective of this multicenter, observational, retrospective study was to assess the incidence rate of ventilator-associated pneumonia (VAP) in coronavirus disease 2019 (COVID-19) patients in intensive care units (ICU). The secondary objective was to assess predictors of 30-day case-fatality of VAP. From 15 February to 15 May 2020, 586 COVID-19 patients were admitted to the participating ICU. Of them, 171 developed VAP (29%) and were included in the study. The incidence rate of VAP was of 18 events per 1000 ventilator days (95% confidence intervals [CI] 16–21). Deep respiratory cultures were available and positive in 77/171 patients (45%). The most frequent organisms were Pseudomonas aeruginosa (27/77, 35%) and Staphylococcus aureus (18/77, 23%). The 30-day case-fatality of VAP was 46% (78/171). In multivariable analysis, septic shock at VAP onset (odds ratio [OR] 3.30, 95% CI 1.43–7.61, p = 0.005) and acute respiratory distress syndrome at VAP onset (OR 13.21, 95% CI 3.05–57.26, p < 0.001) were associated with fatality. In conclusion, VAP is frequent in critically ill COVID-19 patients. The related high fatality is likely the sum of the unfavorable prognostic impacts of the underlying viral and the superimposed bacterial diseases.

Original languageEnglish
Article number555
Pages (from-to)1-13
Number of pages13
JournalJournal of Clinical Medicine
Volume10
Issue number4
DOIs
Publication statusPublished - Feb 2 2021

Keywords

  • Coronavirus
  • COVID-19
  • SARS-CoV-2
  • VAP
  • Ventilation

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint

Dive into the research topics of 'Incidence and prognosis of ventilator-associated pneumonia in critically ill patients with covid-19: A multicenter study'. Together they form a unique fingerprint.

Cite this